drugset
drugset / Trial / NCT01397695

Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01397695 ↗

Phase 2 Completed 20 enrolled University of California, San Diego
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Terence M. Davidson, MD is conducting a research study to find out more about the topical application of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).

Timeline

Start
2009-06
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 100 mg Intranasal

Indications

hereditary hemorrhagic telangiectasia